Summary
Regdanvimab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). No registered clinical trial in this database tests Regdanvimab specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 6 publications for this pair: 3 Cochrane reviews and 3 clinical trial publications. Publication years run from 2021 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Post-Acute COVID/Vaccination Syndrome ranks 675 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 41.0 (trials 0.0, literature 21.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 6 (3 Cochrane reviews, 3 clinical trial publications) |
| Agent type | Biologic |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Regdanvimab to Long COVID / Post-Acute COVID Sequelae (PACVS) in the current OSMF trial extract.
Published literature
- Clinical trial publication A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteersMoench TR, Botta L, Farrer B et al. · EBioMedicine · 2025 · PMID 39923743
- Clinical trial publication Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant periodFomina DS, Lebedkina MS, Iliukhina AA et al. · Frontiers in immunology · 2023 · PMID 37928549
- Cochrane review Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysisAmani B, Amani B · British journal of clinical pharmacology · 2023 · PMID 36717356
- Cochrane review Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)Qaseem A, Yost J, Miller MC et al. · Annals of internal medicine · 2023 · PMID 36442061
- Clinical trial publication Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 InfectionKim JY, Jang YR, Hong JH et al. · Clinical therapeutics · 2021 · PMID 34551869
- Cochrane review SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19Kreuzberger N, Hirsch C, Chai KL et al. · The Cochrane database of systematic reviews · 2021 · PMID 34473343
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Regdanvimab approved for Long COVID / Post-Acute COVID Sequelae (PACVS)?
Regdanvimab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Regdanvimab in clinical trials for Long COVID / Post-Acute COVID Sequelae (PACVS)?
No registered clinical trial in this database tests Regdanvimab specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Regdanvimab in Long COVID / Post-Acute COVID Sequelae (PACVS)?
Synthesis-level literature links Regdanvimab to Long COVID / Post-Acute COVID Sequelae (PACVS), but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.